Teva Pharmaceutical Industries (TEVA) Bank of America Global Healthcare Conference 2025 summary

Capital allocation and innovation

• Focus on paying down net debt, aiming for investment-grade status by the second half of next year, freeing up $400 million in cash by 2027.

• Shifted R&D investment from generics to innovation, reducing generic pipeline coverage to 65% of off-patent drugs for higher returns.

• Operational efficiency program targets $700 million in cost savings by 2027, with two-thirds by end of 2026.

• Business development strategy prioritizes de-risked, synergistic assets globally, including China, to bolster the innovative pipeline.

• Capital allocation remains disciplined, balancing internal growth with external opportunities.

Product pipeline and growth drivers

• Innovative business grew 27% in Q2, offsetting a 2% decline in generics and driving margin and EPS growth.

• Key products Austedo and olanzapine LAI are projected as major growth drivers, with Austedo targeting $3 billion peak sales and olanzapine LAI $1.5–2 billion.

• Upcoming launches and momentum in Uzedy, Ajovy, and DARI expected to sustain growth over the next 12–36 months.

• Olanzapine LAI launch is highly anticipated, leveraging learnings from Uzedy and strong physician excitement.

• DARI positioned to capture pediatric and device-differentiated segments, with a $1 billion opportunity.

Cost efficiency and margin improvement

• $700 million cost savings program includes significant COGS improvements, mainly realized in 2027.

• Site consolidation and operational excellence initiatives are underway, with 14 efficiency programs active.

• COGS improvements expected to enhance gross margin and support profitability beyond 2027.

• Cost efficiency and brand growth are primary levers to offset Revlimid LOE in 2026.